Respiratory syncytial virus (RSV) is a pervasive respiratory infection that primarily affects the lungs and breathing passages, posing significant health risks particularly to infants and older adults. Globally, RSV is a leading cause of hospitalization among young children, contributing to approximately 3.6 million hospital admissions and 110,000 deaths annually in those under five years of age.

The virus is highly contagious and spreads through droplets expelled during coughing or sneezing, as well as through direct contact with contaminated surfaces. Symptoms generally manifest within two to eight days following exposure and often mimic those of a common cold. These include a runny nose, decreased appetite, coughing, sneezing, fever, and wheezing. In very young infants, signs may be less specific, such as irritability, reduced activity, and breathing difficulties.

While most RSV cases are mild, the infection can escalate to severe respiratory illnesses like bronchiolitis and pneumonia, especially in infants and toddlers. These complications may necessitate hospitalization and, in some instances, mechanical ventilation. Children who face greater risk of severe RSV disease include premature infants, those under six months old, and children with chronic lung disease, congenital heart conditions, or compromised immune systems.

Medical experts advise parents to seek urgent care if their child experiences breathing difficulties, wheezing, dehydration, or lethargy. Although there is no targeted antiviral cure for RSV, treatment focuses on symptom management through supportive care. This may involve fever and pain relief, oxygen therapy, or intravenous fluids in more severe cases. Antibiotics are ineffective against RSV, given its viral nature.

Recent advances have improved prevention strategies. A maternal RSV vaccine approved for administration during the third trimester offers newborns passive immunity by transferring protective antibodies from mother to child, critical during the vulnerable early months of life. Additionally, infant immunization with nirsevimab—a long-acting monoclonal antibody—provides protection for at least five months and is recommended as a single-dose injection at birth or as soon as possible thereafter. These innovations have been described as transformative in protecting infants against severe RSV disease during peak seasons.

Alongside vaccination efforts, basic hygiene measures such as frequent handwashing and avoiding contact with infected individuals remain essential to curtail viral spread. Health professionals encourage parents to consult with pediatricians to understand and implement strategies that safeguard children from RSV, aiming to reduce hospitalizations and improve overall public health outcomes.